Podcasts about nbs

Šajās dienās mēs svinam savu brīvību. Bet Ukrainā cilvēki joprojām ziedo dzīvības par savu. Gan karavīri frontē, gan brīvprātīgie, gan mierīgie iedzīvotāji, kuru dzīvi jebkurā brīdī var pārtraukt ienaidnieka raķete vai drons. Kopā ar ukraiņiem cīnās arī karotāji no Latvijas, un mūsu sabiedrība kopumā turpina atbalstīt ukraiņu cīņu, kaut arī rit jau ceturtais kara gads. Mums studijā pievienojas divi no brīvprātīgā atbalsta organizatoriem – Elmārs Pļaviņš, NBS vecākais eksperts starptautiski militāri reliģiskos jautājumos un fonda “Uzņēmēji mieram” vadītāja Laura Skrodele.

Cheltenham's November meeting takes centre stage on this week's podcast with Tom Collins and Ross Millar lining up their best bets for the weekend. In this jam-packed show, the panel look for Festival clues with Albert Bartlett Hurdle, Triumph Hurdle and Arkle Trials. The focus then switches to the weekend's main event, the Paddy Power Gold Cup. NAPs & NBs round off this week's show. Let us know which horse you are looking forward to seeing this weekend below... Hosted on Acast. See acast.com/privacy for more information.

In this edition of First Site, Construction News deputy editor Ben Vogel explores the fast-emerging world of digital product passports and their implications for transparency, accountability and sustainability across the construction supply chain. Joining him to unpack how the technology could reshape regulation, procurement and data management are Peter Caplehorn, chief executive of the Construction Products Association; Dr Stephen Hamil, innovation director at NBS; and Matt Brinklow, sustainability lead at Mace. 

Hostia: Marián Labaj (analytik NBS) a Radovan Geist (šéfredaktor Euractiv). | Myšlienka eurofodov vznikla v Európskej únii v polovici minulého storočia. Bohatšie štáty cez ne prispievajú na rozvoj tých chudobnejších. Pre Slovensko sú eurofondy mimoriadne dôležité, ročne k nám takto pritečú miliardy eur. Mohlo by ale viac. Prečo slabo čerpáme eurofondy? A ako to zmeniť? Počúvajte Kontakty s Evou Sládkovou. | Čerpanie eurofondov. | Moderuje: Eva Sládková; | Kontakty pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. V premiére v pondelok až štvrtok po 20. hodine v Rádiu Slovensko.

After a big weekend of international racing, TC and Ross turn their attention back home for another jam-packed episode. The Grand Sefton Chase takes centre stage at Aintree, supported by the Elite Hurdle and the Badger Beer Handicap Chase at Wincanton. All that before the lads lock in their NAPs and NBs. Got a fancy of your own? Drop it in the comments and see if it matches the panel's picks. Hosted on Acast. See acast.com/privacy for more information.

Pirmā sieviete, kura komandējusi svētku parādi 11. novembra krastmalā. Novembra pirmās nedēļas raidījuma "viens pret vienu" viešņa – pulkvede, NBS štāba bataljona komandiere Antoņina Bļodone.

Kia ora,Welcome to Monday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news rising inflation pressures are now appearing everywhere in the West, underpinned by poor economic judgements.This week will be a busy one on the economic data front, even with the US federal agencies shut down.Locally, all eyes will be on the Q3 labour market data and most observers expect it to show our jobless rate rise to 5.3%.In Australia, the key economic event will be the RBA's rate review late on Tuesday and there will be heightened interest on how they view their rising inflation. That will drive a reassessment by financial markets about where their interest rates are heading. Australia's September trade balance is due and a big surplus is anticipated.Other central banks will chime in this week with rate reviews of their own, including Sweden, Norway and England, among others.In the US while they won't have any official data, focus will turn to the ADP Employment Report, ISM PMIs, and the University of Michigan Consumer Sentiment Index. Canada will release its labour market data too.In China, the October trade surplus is expected to widen to around US$100 bln, although the latest official NBS manufacturing PMI showed a decline in new export orders for October. The broader RatingDog (Caixin) Manufacturing PMI is also expected to signal a further slowdown in factory activity, and its services counterpart will also be closely watched.China's official October PMIs came in over the weekend without any significant improvements from September. They say their factory PMI is now contracting marginally more and a noticeable step lower than last month, and their services PMI is barely expanding, when a small improvement was expected.Japanese industrial production rose +3.4% in September from a year ago, a much better surge in the month than the +0.5% rise that was anticipated.In the US, the Chicago PMI rose in October from its worryingly low August and September levels, but it is still contracting and it has done so for 23 consecutive months now. This month's slight improvement is on the back of a rise in new orders, modest as it may be. Basically this metric is just contracting slower now.But some companies are doing well there. An example is Warren Buffett's Berkshire Hathaway which reported profits of US$48 bln in its latest nine month result, US$31 bln in Q3 alone. They now have cash holdings of US$382 bln. Buffett himself is fading from view now and it will be a challenge for his replacement to maintain the charisma.The EU said its October inflation level is down to 2.1%, the expected dip from September's 2.2%.In Australia, there is more evidence inflation is embedding at levels well above 3%. On Friday they released their Q3 PPI and that came in at 3.5%, unchanged from Q2, and up +1.0% for the latest quarter. Analysts had expected it to reduce.in Q3, but that isn't happening. The RBA will be as unhappy with this as it was with the equally high CPI result. Only recently a rate cut tomorrow was a sure bet, but no longer.And staying in Australia, bank lending grew +7.3% in September, up +6.3% for housing but up +9.5% for business from the same month a year ago. But there is a noticeable dip in business lending in September from August which surprised some. Going the other way, observers were equally surprised by the monthly surge in housing loans.The surge is worrying APRA. The combination of demand from the FHB guarantee scheme, and exuberance by investors is joining to create the rush. And it is only expected to increase. So the regulator is stepping in with warnings to banks to reign in the party. High DTI lending is their special focus.The UST 10yr yield is now at 4.10%, unchanged from Saturday at this time. The price of gold will start today at US$4001/oz, down -US$5 from this time Saturday. That is down -US$107 from this time last week. But it is up +US$141 or +3.6% for the month.American oil prices are+50 USc firmer from Saturday at just on US$61/bbl, with the international Brent price now just over US$64.50/bbl.The Kiwi dollar is now at just on 57.2 USc, and down unchanged from Saturday. It is down -20 bps for the week, and down -70 bps or -1.2% for the month. Against the Aussie we are unchanged at 87.5 AUc. Against the euro we are also little-changed at 49.7 euro cents. That all means our TWI-5 starts today at just over 61.8 and down -30 bps from yesterday, down -20 bps for the week, down -40 bps for the month.The bitcoin price starts today at US$110,113 and up +0.8% from this time Saturday. Volatility over the past 24 hours has been low at just on +/- 0.6%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

After a thrilling weekend at Cheltenham, the TC and Ross return for Wetherby and Ascot. The Charlie Hall Chase, and the Sodexo Gold Cup are followed by their NAPs and NBs. It's then passports at the ready as they touchdown in California for the Breeders' Cup and Australia for the Melbourne Cup. Hosted on Acast. See acast.com/privacy for more information.

Show Notes: Shifting political priorities and economic pressures over the past couple of years have seen several countries scale back climate commitments contributing to the growing gap between climate pledges and real-world emissions (still rising).What does this mean for a ‘Just Transition' and Net Zero? While there is no silver bullet, IUCN and UNEP emphasise Nature based Solutions (NbS) can be pivotal for climate mitigation and adaptation, when pursued alongside rapid decarbonisation globally.To discuss NbS, and climate change I recently caught up with Swapan Mehra a global leader in climate action and ecosystem conservation. In this deeply insightful conversation Swapan spoke about how NbS is a holistic approach to addressing the climate crisis, through a spectrum of actions designed to protect and restore ecosystems while simultaneously delivering co-benefits for biodiversity, communities and individuals. We also spoke about…

China's industrial profits grew at its fastest pace in nearly two years in September, official data showed on Monday, as policy measures to rein in rat-race competition helped ease pressure on manufacturers despite lingering domestic and external headwinds.官方数据于周一显示，尽管国内外不利因素仍存，但随着遏制无序竞争的政策措施帮助缓解了制造商的压力，9月中国工业利润增速达到近两年来的最高水平。Analysts attributed the rebound in corporate profitability to firmer prices and resilient industrial output, supported by Beijing's pro-growth policies, pointing to a stabilizing economy buoyed by the strong performance of the new quality productive forces.分析师认为，在国家稳增长政策的支撑下，产品价格趋稳以及工业产出保持韧性，推动了企业盈利能力的回升。他们指出，得益于新质生产力的良好发展态势，中国经济正趋于稳定。Looking ahead, they expect the recovery momentum to extend into the fourth quarter, with policymakers likely to intensify countercyclical adjustments to boost domestic demand, spur market confidence and reinforce internal growth drivers — keeping China on track to meet its full-year growth target.展望未来，分析师预计复苏势头将延续至第四季度。政策制定者可能会加大逆周期调节力度，以扩大内需、提振市场信心并强化内生增长动力，确保中国能够实现全年经济增长目标。China's industrial enterprises with an annual revenue of at least 20 million yuan ($2.8 million) saw their total profits soar 21.6 percent year-on-year in September, following a 20.4 percent jump in August, marking the largest gain since November 2023, data from the National Bureau of Statistics showed on Monday.国家统计局周一发布的数据显示，9月，年营业收入2000万元（约合280万美元）及以上的中国工业企业，其实现利润总额同比激增21.6%；8月该指标同比增幅为20.4%。这意味着9月工业利润增幅创下2023年11月以来的最高纪录。During the first nine months of the year, profits at major industrial companies grew to 5.37 trillion yuan, a year-on-year increase of 3.2 percent, following a 0.9 percent rise in the first eight months.今年前9个月，规模以上工业企业实现利润5.37万亿元，同比增长3.2%；前8个月该指标同比增幅为0.9%。Wen Bin, chief economist at China Minsheng Bank, said: "The strong growth in September's industrial profits was largely driven by a low base from last year, combined with stabilizing production, easing price pressures and improving profit margins."中国民生银行首席经济学家温彬表示：“9月工业利润的强劲增长，很大程度上得益于去年同期的低基数效应，同时也受到生产企稳、价格压力缓解以及利润率改善等因素的综合推动。”NBS data showed China's industrial output surged 6.5 percent year-on-year in September after a 5.2 percent rise in August, marking the first acceleration in three months.国家统计局数据显示，9月中国工业增加值同比增长6.5%，较8月的5.2%有所提升，这是该指标近三个月来首次出现增速加快。Meanwhile, China's producer price index — which measures factory-gate prices — fell 2.3 percent year-on-year in September, easing from a 2.9 percent drop in August.与此同时，9月中国工业品出厂价格指数（PPI，衡量工厂端产品价格水平）同比下降2.3%，降幅较8月的2.9%有所收窄。Wen also noted that "structural bright spots are a key part of the rebound in corporate profitability", underpinned by the robust performance of high-tech manufacturing and equipment manufacturing sectors.温彬还指出，“结构性亮点是企业盈利能力回升的关键因素”，而高新技术制造业和装备制造业的强劲表现为这一亮点提供了支撑。According to the NBS, profits in high-tech manufacturing industries surged 26.8 percent in September, driving overall industrial profit growth to accelerate by 6.1 percentage points.国家统计局数据显示，9月高新技术制造业利润同比激增26.8%，拉动全部工业利润增速加快6.1个百分点。For the first nine months, profits in equipment manufacturing industries soared 9.4 percent, contributing 3.4 percentage points to overall profit growth.今年前9个月，装备制造业利润同比大幅增长9.4%，对全部工业利润增长的贡献率达到3.4个百分点。Citing the faster profit growth among private sector and foreign companies, Wen said that it indicates market expectations are improving, and business confidence is recovering.温彬提到，私营企业和外资企业利润增速加快，这表明市场预期正在改善，企业信心逐步恢复。Looking ahead, he said the fourth quarter will likely see steady growth in industrial profits with the government's effective measures to curb involution competition, easing price pressures and improving corporate profitability.他表示，展望未来，随着政府采取有效措施遏制行业内卷、价格压力进一步缓解以及企业盈利能力持续改善，第四季度工业利润有望保持稳定增长。In the communique of the fourth plenary session of the 20th Central Committee of the Communist Party of China, which was released on Thursday, policymakers called for "resolutely achieving the economic and social targets set for this year", suggesting they will ensure GDP growth will reach the "around 5 percent" growth target.中共二十届四中全会公报于周四发布，其中政策制定者提出“坚决完成今年经济社会发展目标任务”，这一表述意味着政府将确保国内生产总值（GDP）实现“5%左右”的增长目标。Lu Ting, chief China economist at Nomura, said he expects the country to refocus on short-term growth stability. "Beijing just needs around 4.2 percent GDP growth in the fourth quarter to deliver that target. So, from a statistics perspective, it's easily within reach," he said.野村证券首席中国经济学家陆挺表示，预计中国将重新聚焦短期经济稳定增长。他指出：“要实现全年增长目标，中国第四季度GDP增速只需达到4.2%左右即可。因此，从统计角度来看，这一目标触手可及。”The best strategy is to resist the temptation to fuel the stock markets by avoiding too high-profile monetary measures in the near term, remaining vigilant by avoiding contractionary policies, cleaning up the property market problem, and addressing some deep-rooted problems such as the unequal social security system, Lu said.陆挺认为，当前最佳策略是：短期内避免推出过于高调的货币政策，抵制刺激股市的诱惑；保持警惕，不采取紧缩性政策；着力解决房地产市场问题；并应对一些深层次问题，如社会保障体系不均衡等。A report released by the Chinese Academy of Social Sciences' Institute of Finance & Banking on Monday noted that insufficient effective demand remains a prominent challenge.中国社会科学院金融研究所周一发布的一份报告指出，有效需求不足仍是当前面临的突出挑战。Against the backdrop of US-China trade friction and profound structural economic shifts, the report said China should advance macroeconomic governance system innovation that addresses both existing structures and new growth drivers, with a focus on enhancing policy efficacy.报告称，在美国对华贸易摩擦以及国内经济结构性深刻调整的背景下，中国应推进兼顾现有结构与新增动力的宏观经济治理体系改革，并重点提升政策实施效果。"In the short term, macro policies should be proactively strengthened, including more forceful fiscal spending tilted toward consumption stimulation, utilizing the room for interest rate cuts and reserve requirement ratio reductions created by the US Federal Reserve's move, and implementing multi-pronged measures to stabilize the property market and foster its high-quality development," said Wang Qing, assistant researcher at the institute.该研究所助理研究员王青（音译）表示：“短期内，应积极加大宏观政策力度，包括采取更有力的财政支出措施并向刺激消费倾斜、利用美联储政策调整所带来的降息降准空间，以及通过多方面举措稳定房地产市场、推动其高质量发展。”resilient/rɪˈzɪliənt/adj.能快速恢复的，具韧性的countercyclical/ˌkaʊntəˈsaɪklɪkl/adj.反经济周期的

Hostia: Matej Horňák (makroekonomický analytik Slovenskej sporiteľne) a Ľuboslav Kačalka (ekonomický novinár a komentátor magazínu Forbes). | Agentúra Standard & Poor's podržala rating Slovenska na úrovni A+, no s negatívnym výhľadom. V porovnaní s agentúrami Fitch a Moody's je to stále najlepšie hodnotenie – tie by mali známku opäť prehodnocovať v závere roka. Je udržanie známky od S&P potvrdením zodpovedného riadenia verejných financií? Ako stav interpretuje minsterstvo financií? Je hodnotenie agentúry v kontraste s tým, aký vývoj ekonomiky očakávajú iné inštitúcie ako RRZ a NBS? Líšia sa metodiky, podľa ktorých jednotlivé agentúry posudzujú rating krajiny? Čo všetko berú do úvahy a s akou váhou? Do akej miery je vývoj v rukách Slovenska, ak aj S&P konštatuje negatívne globálne vplyvy? Ako sa mení pohľad ratingových agentúr na ostatné krajiny v regióne resp. v Európe? Čo udržanie ratingu znamená pre krajinu v praxi, resp. čo by znamenalo jeho zhoršenie a ako rýchlo by sa prejavilo? Ako výrazne by sa zmenili napríklad náklady krajiny na obsluhu dlhu, hodnota štátnych dlhopisov? Aké sú možné sekundárne efekty na súkromný sektor (úvery pre firmy a domácnosti, investičné rozhodnutia)? Aký vývoj ratingov môžeme očakávať v budúcnosti? | Slovensko v očiach ratingových agentúr. | Moderuje: Soňa Mačor Otajovičová; | Diskusiu Z prvej ruky pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. Vysielame každý pracovný deň o 12:30 v Rádiu Slovensko.

Tuomas Enbuske Huumeet, TV ja usko [SIC] | #neuvottelija 357. Tuomas Enbuske ja Sami keskustelevat Tuomaksen kirjasta Tuomas Enbuske Elämänkerta [SIC], Docendo 2025.00:00 Enbuske-elämänkerran [SIC]-nimen tausta ja merkitys01:04 Tahallinen kirjoitusvirhe markkinointina ja somereaktio01:22 Suhde Tuomakseen ja Kiss FM:n alkuaikojen muistelua02:00 Sidekick-rooli, straight man -asetelma ja Frasierin esimerkki02:37 Seksuaalinen jännite radiossa, ursti Hyppösen ja Pääskysaaren välillä03:28 Flirttailun hienovaraisuus ja kolmannen pyörän spekulointi03:46 Hyppösen ratkaiseva rooli Enbusken uran alussa04:18 Laajasalon opisto, erilaisuuden hyödyntäminen ja media-alan ponnahduslauta05:13 Hyppösen vaikutus aitopuheen tuomisessa radioon05:34 Ryhmäseksikeissi ja poliisikuulustelun absurdius06:38 Vastuun kantaminen ja Kajusniemi-sivupolku07:19 “Tee mitä tahansa radiossa” -osio ja suorien lähetysten rajat08:34 Ilkka Kylävaaran rikosilmoitus ja mediakohun jälkipyykki09:04 Laajasalon alumnit ja opiston merkitys urapoluille10:17 Pappishaave ja opiskelun vaatimukset10:43 Paparatsi Hörkkö -podcast ja Aku Hirviniemi -paljastus12:13 Kokaiiniviittaukset, julkinen vastaanotto ja median kaksoisstandardi13:49 TV-formaattien kehitys, Enbusken show't ja oman uran reflektointi15:10 Maikkarin juontajakeissi, Saku Tuominen ja 2000-luvun media16:03 Rahan runsaus ja kotimaisten formaattien kato17:24 Faroutin kansainvälinen myynti ja 9/11:n vaikutus lentoteemaan19:17 Arjen rutiinit, hygienia ja elämän hallinta20:29 NBS, palkkakeskustelu ja kaksisuuntaisen sairauden puhkeaminen22:16 Marja Veitolan vaikutus ja median sukupuoliroolit23:07 Laskutus, palkka, verotus ja talousopetuksen puute24:27 Mania–tuhlailu–säästäminen ja litiumin pelastava rooli25:53 Kokaiinijakso, USA-matka ja riippuvuuden vaarat28:20 Huumeiden vaikutukset, kaksisuuntaisuus ja älykkyyskorrelaatio30:15 Psykedeelit, Sam Harris ja moral landscape -keskustelu30:58 Alkoholi ja kannabis eri tavoin vaarallisina33:22 Humalapersoonat, tehdasasetukset ja kontrollin katoaminen34:12 Simon Baron-Cohenin mallit, neuroepätyypillisyys ja yhteensopivuus35:34 Hullun paperit -sarja ja Jouko Pihon profetiat36:36 Suomen nostatus -podcast, maksumalli ja yleisön analyysit38:23 Samppanjan sapelointi, ironinen yläluokkahuumori39:02 Taide, Osmo Rauhala, abstraktit teemat ja irrationaalinen puoli41:16 Faking it, Cattelan banaani ja taiteen aitous42:31 Taiteen ihmisyyttä vahvistava merkitys43:16 Uskon synty Wahlroosin keskustelusta ja ateismin hiipuminen45:00 Naapuriapu, Sanna Ukkola ja hoitoon hakeutuminen46:21 Uskon aitous, Dawkinsin pehmeneminen ja Peterson-vertailu48:19 Podcastien rooli uusina kolumneina ja korkea–matala -dynamiikka49:06 Demariminuuttisketsi ja ironinen kelloinnovaatio49:46 Elämänkerta osa yksi ja äänikirjajulkaisu#neuvottelija Sisäpiirissä panojuttuja Tuomaksen kanssaKatso Sisäpirijaksot ja tue Samiahttps://www.youtube.com/channel/UCRI34L9OtDJuZpaWicbNXzg/join#neuvottelija Sami Miettinen

After a dramatic Champions Day last weekend, attentions now turn to Cheltenham for their October showcase meeting. On this week's podcast we are covering two races from Pestbury Park as well as the Futurity Stakes at Doncaster and Newbury's St Simon Stakes. TC and Ross round off this week's podcast with their NAPs and NBs from across Saturday's action.Let us know any horses you fancy this weekend or a jumps horse to follow for the season... Hosted on Acast. See acast.com/privacy for more information.

I denne episoden møter vi Tor Jacob Solberg – bonden som gikk fra to kyr knytt til ei bjørk til å lede Norsk Bonde- og Småbrukarlag. Tor Jacob er kjent for sitt engasjement, sin optimism og evne til å utfordre systemet – enten det handler om selvforsyning, klima, eller hvordan vi kan bygge et mer rettferdig og robust norsk landbruk.I episoden snakker vi om reisen hans, om hva som må endres i norsk landbruk, litt om bondeopprøret, forskjellen på NBS og Bondelaget, rovdyrpolitikk, klimaavtalen i jordbruket, hva slags framtid han ser for norsk matproduksjon - og mye mer!God lytt!

Akademický sochár, autor sochy Imricha Karvaša pred budovou Národnej banky Slovenska či série občania, sochy horolezcov, ktoré sú inštalované aj v budove Slovenského rozhlasu. Pracuje s tradičnými i novými materiálmi (betón, kameň, drevo, železo, silikón, sklo, vosk, živice a pod.). Východiskovou a základnou tvorivou platformou jeho sochárstva je životná vášeň pre horolezectvo, ktorému sa už roky venuje aktívne. Jeho diela vystavujú galérie na celom svete. Vyštudoval odbor socha na bratislavskej VŠVU u profesora Jozefa Jankoviča, na strednej škole študoval rezbárstvo. Študoval aj v belgickom Gente. Pochádza z Ružomberka. Má päť dcér a jedného syna. | Hosť: Štefan Papčo (akademický sochár, autor sochy Imricha Karvaša pred budovou NBS). | Moderuje: Kata Martinková. | Tolkšou Nočná pyramída pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1.

British Champions Day is here, bringing with it a stacked card including four Group 1 races. Each race is analysed in detail by both Ross and TC with the Champion Stakes serving up a mouth-watering clash between Ombudsman and Delacroix, but who will our pundits side with? NAPs and NBs from across the country round off this action-packed podcast. Think you've found a winner on Champions Day? Let us know below. Hosted on Acast. See acast.com/privacy for more information.

Realita verzus sen, alebo realita a snaha o jej prekrytie? Otázky, ktoré sa natískajú po víkendovom snemovaní vládneho Smeru. Robert Fico ponúkol svojej strane „Desatoro“, ktorého deklarovaným cieľom sú riadne, nie predčasné voľby a víťazstvo Smeru.Ako to vyznieva v čase, keď prieskumy verejnej mienky zachytávajú len ďalší prepad jeho strany; keď kladie nohu do dverí pri návrhu opätovnej voľby Petra Kažimíra do čela NBS, ktorého sa nechce vzdať koaličný Hlas; keď otvára tému predlžovania mandátu obecných zastupiteľstiev; keď čelí zdražovaniu, konsolidačnému tlaku a rastúcemu zadlžovaniu krajiny, čo kritizuje aj rozpočtová rada.Pozrieme sa na to politológom Radoslavom Štefančíkom.Budete počuť aj Vladimíra Amricha, s ktorým sa pozrieme na vládny návrh štátneho rozpočtu, ako i na jeho hodnotenie zo strany Rady pre rozpočtovú zodpovednosť.Podcast pripravil Jaroslav Barborák.

Realita verzus sen, alebo realita a snaha o jej prekrytie? Otázky, ktoré sa natískajú po víkendovom snemovaní vládneho Smeru. Robert Fico ponúkol svojej strane „Desatoro“, ktorého deklarovaným cieľom sú riadne, nie predčasné voľby a víťazstvo Smeru.Ako to vyznieva v čase, keď prieskumy verejnej mienky zachytávajú len ďalší prepad jeho strany; keď kladie nohu do dverí pri návrhu opätovnej voľby Petra Kažimíra do čela NBS, ktorého sa nechce vzdať koaličný Hlas; keď otvára tému predlžovania mandátu obecných zastupiteľstiev; keď čelí zdražovaniu, konsolidačnému tlaku a rastúcemu zadlžovaniu krajiny, čo kritizuje aj rozpočtová rada.Pozrieme sa na to politológom Radoslavom Štefančíkom.Budete počuť aj Vladimíra Amricha, s ktorým sa pozrieme na vládny návrh štátneho rozpočtu, ako i na jeho hodnotenie zo strany Rady pre rozpočtovú zodpovednosť.Podcast pripravil Jaroslav Barborák.

Tretia konsolidácia Ficovej vlády ohrozila sociálny zmier. Proti konsolidácii aj rozpočtu protestujú odborári aj opozícia. Vláda zmrazila trináste dôchodky a Smer navyše hovorí o ich adresnosti. Stámilióny na energopomoc nemôže vláda zaplatiť z eurofondov. Konsolidácia dostáva trhliny a neverí je ani Národná banka.Čo s tým urobí vládny Hlas a čo chce urobiť s tým, že mu už rok padajú voličské preferencie? Prečo je podľa premiéra Peter Kažimír zradca a prečo NBS neverí vládnej konsolidácii? A čo hovorí Hlas na nápad premiéra posunúť voľby do obcí, miest a krajov o ďalší rok? Aký je na to vlastne dôvod?Braňo Závodský sa rozprával s ministrom práce sociálnych vecí a rodiny a podpredsedom strany Hlas – SD Erikom Tomášom.

It's another big weekend of racing, and the SBK Betting Podcast crew are back with plenty to "jump" into. On the main card: the Dewhurst Stakes, the Cesarewitch Handicap, and the Silver Trophy. Away from that, Tom Collins takes a swing at York's Sprint Trophy, while Ross Millar has his eye on the Welsh Champion Hurdle from Chepstow. Add in their NAPs and NBs, and you've got your weekend sorted. Got a fancy of your own? Let us know in the comments... Hosted on Acast. See acast.com/privacy for more information.

Yesterday, Building and Construction Minister Chris Penk announced changes to the earthquake-prone building regulations that will remove nearly 3000 buildings from the classification register.   Previously, buildings would have to meet a 34%NBS (new building standard) threshold to predict likelihoods of withstanding seismic action. The new system instead prioritises identifying structures that pose a higher risk to human life. Alterations seek to measure risk in a manner that balances safety with more affordable and realistic remediation action for existing properties.   Producer Jasmine Gray spoke to Dr. Megan Boston, Senior Lecturer for Civil Engineering, at the University of Waikato about what the new quake-prone building regulations mean for Aotearoa's community safety and heritage.

Yesterday, Building and Construction Minister Chris Penk announced changes to the earthquake-prone building regulations that will remove nearly 3000 buildings from the classification register.   Previously, buildings would have to meet a 34%NBS (new building standard) threshold to predict likelihoods of withstanding seismic action. The new system instead prioritises identifying structures that pose a higher risk to human life. Alterations seek to measure risk in a manner that balances safety with more affordable and realistic remediation action for existing properties.   Producer Jasmine Gray spoke to Dr. Megan Boston, Senior Lecturer for Civil Engineering, at the University of Waikato about what the new quake-prone building regulations mean for Aotearoa's community safety and heritage.

Hostia: Miroslav Gavura (vedúci Oddelenia prognóz a modelov NBS) a Branislav Žúdel (riaditeľ Odboru makroekonomických analýz a prognóz IFP). | NBS znížila odhad ekonomického rastu v tomto roku na 0,8 %, na jar ešte rátala s 1,2-percentným rastom. Tempo rastu by malo v budúcom roku ďalej klesať. Vplyv konsolidácie na verejné financie bude podľa NBS menší, ako predpokladá ministerstvo financií - dosiahne len 1,6 miliardy eur namiesto komunikovaných 2,7 miliardy. Centrálna banka aktuálne predpokladá, že v prognózovanom období príde Slovensko asi o 30-tisíc pracovných miest. Inflácia zostane v dôsledku čiastočného uvoľňovania cien energií pre domácnosti podľa NBS zvýšená, okolo 3,5 %. Zhoršenú kondíciu ekonomike predikujú aj analytici IFP na MinFin. Aj podľa nich vzrastie hrubý domáci produkt v roku 2025 len o 0,8 %. V roku 2026 by sa malo tempo rastu zvýšiť na 1,3 %, pomôcť majú najmä zdroje z plánu obnovy. Nezamestnanosť sa v dôsledku nižšieho dopytu po práci v budúcom roku mierne zvýši na 5,6 %. IFP v aktuálnej prognóze očakáva, že inflácia v tomto roku zrýchli na 4,1 %. Z čoho plynie rozdielny odhad budúceho vývoja tempa rastu slovenskej ekonomiky? Ako hodnotíte riziko, že pri nízkom raste sa zvýši tlak na verejné financie (dlh, ratingy) a že to vyústi do vyšších obslužných nákladov dlhu? Zdieľa MinFin skepsu NBS (a RRZ) v očakávanej miere vplyvu konsolidácie na verejné financie? Možno očakávať v budúcom roku rast miezd aj v kontexte konsolidačných opatrení a ako sa odrazí v reálnych príjmoch domácností? Budú domácnosti naďalej schopné držať svojou spotrebou ekonomiku nad vodou? Aké konkrétne sektory budú najviac ovplyvnené predikovanou stratou pracovných miest? Aké nástroje politiky trhu práce sú podľa vás najefektívnejšie a mali by byť prioritou už teraz? | Experti znížili odhad rastu ekonomiky. | Moderuje: Juraj Jedinák; | Diskusiu Z prvej ruky pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. Vysielame každý pracovný deň o 12:30 v Rádiu Slovensko.

It's a blockbuster weekend of racing and the SBK Betting Podcast crew have it all covered. The stage is set for the final Classic of the season with the St Leger at Doncaster, the Irish Champion Stakes at Leopardstown, and the Irish St Leger at the Curragh on Sunday. Expect strong views and tips before the panel lock in their NAPs & NBs. Ross even stuck to the flat this week. Think you've spotted a winner? Drop your shout in the comments. Hosted on Acast. See acast.com/privacy for more information.

台灣歷史最久的環境藝術祭「關渡國際自然藝術季」，今年即將於9月14日起在關渡自然公園登場，並持續至12月31日，迎來具有紀念意義的20週年！25年來，由台北鳥會認養經營的關渡自然公園，以棲地保育與環境教育作為核心工作，為民眾守護淡水河畔的重要濕地生態，成果已獲得國際獎項肯定。而「關渡國際自然藝術季」則成為其中的一環，讓藝術成為推廣與連結自然的方式。本屆藝術季以「看見關渡：自然作為一個解方」為策展主題，呼應全球關注的自然解方（Nature-based Solutions, NbS），也彰顯藝術季一直以「自然為主」策展方向。自然不僅是展覽的主題與場域，更是創作的媒材，展現藝術與環境「三位一體」的獨特關係。藝術家李蕢至（左2）指導緯創資通志工進行作品《浮脈》的製作。今年共有7組藝術家／團隊參與，其中6組曾在過去藝術季創作，再度回到關渡延續對土地的回應。像是美國藝術家Herb Parker、立陶宛藝術家Arvydas Ališanka、南韓藝術家Bonggi Park，以及台灣藝術家李蕢至，都以新作呈現人與自然的互動。荷蘭行為藝術家Ieke Trinks，則是首次造訪關渡的藝術家，他將以展演、參與的方式進行創作。社區性的參與也是關渡自然藝術季的軸心之一，今年北藝大藝教所與關渡國中學生也透過協同共創，讓更多年輕世代參與其中。緯創志工學習輪口編技法，用以製作《浮脈》的窗戶。除了藝術家，志工群體的參與也成為藝術季的重要亮點。除了各藝術家都有志工協助外，今年李蕢至創作的作品《浮脈》，更集結了52位緯創資通的志工攜手完成。創作過程從採集、整理自然素材開始，體現「共同創造」的力量。在關渡國際自然藝術季，自然、藝術與人相會，共同構築一場彼此交融的感官體驗。現在就讓我們一起透過聲音，走進這場藝術盛會！緯創資通董事長林憲銘（前排左3）出席《浮脈》的揭幕儀式，與志工同樂。

Haydock and Kempton take centre stage this weekend, where the SBK Betting Podcast crew break down the Superior Mile, the September Stakes, and the headline act, the Sprint Cup with strong opinions, lively debate, and their NAPs & NBs to round off the show. Got a selection of your own? Let us know Hosted on Acast. See acast.com/privacy for more information.

The spotlight this Saturday falls on the Atlanta Stakes and Solario Stakes at Sandown and yes, the SBK Betting Podcast panel have plenty of opinions for it. Expect sharp insights, and of course their NAPs & NBs to round things off. Got a fancy of your own? Let us know Hosted on Acast. See acast.com/privacy for more information.

One of the most popular terms in conservation these days is “nature-based solutions” (NbS). The concept is centered around the various ways in which conservation (including restoration and sustainable use) can benefit society, economy and environment. NbS are alternatives to engineered solutions to these problems, which benefit people as well as nature. Sounds straightforward, and the concept has been taken up in government policy and largely embraced by conservation science. And yet it has been somewhat divisive, for very different reasons.Joy Ommer is scientific lead at KAJO, a Slovakia-based geoservices consultancy focused on disaster risk reduction and management. In a recent paper she and some project partners write about the importance of understanding the impacts of nature-based solutions before they are actually implemented. We discussed this and other issues around the NbS concept.Links to ResourcesQuantifying co-benefits and disbenefits of Nature-based Solutions targeting Disaster Risk Reduction - 2022 article in the International Journal of Disaster Risk Reduction by Joy and co-authors, which we refer to in our discussionNature-based solutions: using the power of nature - Some examples of NbS on an IUCN webpageVisit www.case4conservation.com

York's Ebor Meeting rolls on, and the SBK Betting Podcast crew are back to tackle Saturday's card. On the agenda: the Melrose Handicap, the City of York Stakes, and of course the big one the Ebor Handicap.Expect bold tips as they reveal their NAPs and NBs to round off the show. Got a fancy for the Ebor yourself? Let us know Hosted on Acast. See acast.com/privacy for more information.

JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, “Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.” Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this population. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and associate professor at the OU Health Stephenson Cancer Center. Today, we are excited to be joined by Dr. Alison Schram, Associate Attending Physician and Section Head of Oral Therapeutics with Early Drug Development and Gynecologic Medical Oncology Services at the Memorial Sloan Kettering Cancer Center, and the senior author of the JCO Precision Oncology article titled, "Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Schram, thank you for joining us today. I am excited to be discussing this very interesting, unique topic based on what you published in JCO PO. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: What we like to do for these podcasts is try to make them scientifically interesting but at the same time, keep them at a level where our trainees and other community oncology professionals understand the implications of what you've published. So I'd like to start by asking you, what is leiomyosarcoma for those of us who don't necessarily know a lot about leiomyosarcoma, and what are some of the treatment options for these uterine sarcomas? Dr. Alison Schram: Uterine leiomyosarcoma is a rare subtype of uterine cancer, and it represents about 1% of all female cancers in the reproductive tract. This is a rare malignancy that arises from the myometrial lining of the uterus, and it is generally pretty aggressive. In terms of the standard therapy, the standard therapy for uterine leiomyosarcoma includes chemotherapy, generally combination chemotherapy, but despite a few regimens that tend to be effective, the duration of effectiveness is relatively short-lived, and patients with advanced uterine leiomyosarcoma eventually progress and require additional therapy. I will say that localized uterine leiomyosarcoma can be treated with surgery as well. Dr. Rafeh Naqash: Thank you for that description. Now, there are two aspects to what you published. One is the sarcoma aspect, the leiomyosarcoma, and the second is the BRCA mutation. Since we are a precision medicine journal, although we've discussed BRCA a couple of times before, but again, for the sake of our listeners, could you highlight some of the aspects of BRCA and PARP sensitivity for us? Dr. Alison Schram: Yes. So BRCA is a gene that's important for DNA repair, and BRCA mutations can be either inherited as a germline mutation, so one of your parents likely had a BRCA mutation and you inherited one copy. In patients who have an inherited BRCA mutation, the normal cells tend to have one abnormal copy of BRCA, but if a second copy in the cell becomes altered, then that develops into cancer. And so these patients are at increased risk of developing cancers. Specifically, they are at an increased risk of developing ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and a few others. These cancers are considered BRCA-associated tumors. Alternatively, some patients, more rarely, can develop BRCA-altered cancers completely sporadically. So it's a mutation that happens in the tumor itself, and that can lead to impaired DNA repair and promote cancer progression. And those patients are not, they don't have any inherited risk, but just a random event caused a BRCA mutation in the tumor. The reason this is important is because, in addition to it being potentially important for family members, there are certain treatments that are more effective in BRCA-altered cancers. And the main example is PARP inhibitors, which are small molecule inhibitors that inhibit the PARP enzyme, and there is what we call synthetic lethality. So PARP is important for DNA repair, for single-stranded DNA repair, BRCA is important for double-stranded DNA repair, and in a patient that has a cancer that has a BRCA mutation, that cancer becomes more reliant on single-stranded DNA repair. And if you inhibit it with a PARP inhibitor, the cancer cells are unable to repair DNA, and the cells die. So we call that synthetic lethality. PARP inhibitors are FDA approved in several diseases, predominantly the BRCA-associated diseases I mentioned: breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Dr. Rafeh Naqash: That was very beautifully explained. Honestly, I've heard many people explain BRCA before, but you kind of put it in a very simple, easy to understand format. You mentioned this earlier describing germline or hereditary BRCA and somatic BRCA. And from what I gather, you had a predominant population of somatic BRCA, but a couple of germline BRCA as well in your patient population, which we'll go into details as we understand the study. You mentioned the second hit on the germline BRCA that is required for the other copy of the gene to be altered. In your clinical experience, have you seen outside of the study that you published, a difference in the sensitivity of PARP for germline BRCA versus a somatic BRCA that has loss of both alleles? Dr. Alison Schram: So we will get into what's unique about uterine sarcomas in just a minute. In uterine sarcomas, what we have found is that the BRCA mutations tend to be somatic and not germline, as you mentioned. That is in contrast to the other diseases we mentioned, where the vast majority of these tumors are in patients that have germline BRCA alterations. So one thing that's really unique about the uterine sarcoma population and our paper, I believe, is that it is demonstrating an indication for PARP inhibitors in a population that is not characterized by germline BRCA alterations, but truly these by somatic BRCA alterations. If you look at the diseases that PARP inhibitors are validated to be effective in, including the, you know, the ones I mentioned, the BRCA-associated tumors, there's some data in specific context that suggests that perhaps germline alterations are more sensitive to PARP inhibitors, but that's not universal, and it's really tricky to do because the genetic testing that we have doesn't always tell you if you have two hits or just one hit. So you need more complex genetic analysis to truly understand if there is what we call a biallelic loss. And sometimes it's not a second mutation in BRCA. Sometimes it's silencing of the gene by hypermethylation or epigenetics. Some of our clinical trials are now incorporating this data collection to really understand if biallelic loss that we can identify on more complex genetic testing predicts for better outcomes. And we think it's probably true that the patients that have biallelic loss, whether it be germline or somatic biallelic loss, are more likely to benefit from these treatments. That still needs to be tested in a larger cohort of patients prospectively. Dr. Rafeh Naqash: In your clinical experience, I know you predominantly use MSK-IMPACT, but maybe you've perhaps used some other NGS platforms, next-generation sequencing platforms. Have you noticed that these reports for BRCA alterations the report mentioning biallelic loss in certain cases? I personally don't- I do lung cancer, I do early-phase lung cancer as well, but I personally don't actually remember if I've seen a report that actually says biallelic loss. So after this podcast, I'm going to check some of those NGS reports and make sure I look at it. But have you seen it, or what would be a learning point for the listeners there? Dr. Alison Schram: Exactly. And they usually do not. They usually do not explicitly say, “This looks like biallelic loss,” on the reports. The exception would be if there's a deep deletion, then that implies both copies of the gene have been deleted, and so then you can assume that it's a biallelic loss. But oftentimes, when you see a frameshift alteration or a mutation, you don't know whether or not it's a biallelic loss. And you may be able to get some clues based on the variant allele frequencies, but due to things like whole genome duplication or more complex tumor genomics, it's not clear from these reports, and you really do need a more in-depth bioinformatic analysis to understand whether these are biallelic or not. So that is why I suggest that this really needs to be done in the context of a clinical trial, but there is definitely a theoretical rationale for reporting and treating patients with biallelic losses perhaps more so than someone who has a variant of unknown significance that seems to be monoallelic. The other tricky part, as I mentioned, is the fact that there could be epigenetic changes that silence the second copy, so that wouldn't be necessarily evident on a DNA report, and you would need more complex molecular testing to understand that as well. Dr. Rafeh Naqash: Sure. Now, going to your study, could you tell us what prompted the study, what was the patient population that you collected, and how did you go about this research study design? Dr. Alison Schram: It's actually a great story. I was the principal investigator for a clinical trial enrolling patients regardless of their tumor type to a combination of a PARP inhibitor and immunotherapy. And this was a large clinical trial that was being done as a basket study, as I mentioned, for patients that have either germline or somatic alterations with advanced solid tumors that had progressed on standard therapy. And the hypothesis was that the combination of a PARP inhibitor and immunotherapy would be synergistic and that there would be increased efficacy compared to either agent alone and that patients who had BRCA alterations were a sensitive population to test because of their inherent sensitivity to PARP inhibitors and perhaps their increased neoantigen burden from having loss of DNA repair. So this large study, it's been published, really did show that there was efficacy across several tumor types, but it didn't seem to clearly demonstrate synergy between the immunotherapy and the PARP inhibitor as compared to what you might expect from a PARP inhibitor alone, and in addition to a couple of cases, perhaps attributable to the immunotherapy. So maybe additive rather than synergistic efficacy. However, what really struck me looking at the data was that there were three patients with uterine leiomyosarcoma with BRCA deletions who had the best responses of anyone on the study. So incredible, durable responses. One of my patients with a complete response that continues to not have any evidence of cancer eight years after the initiation of this regimen. And for those of us that treat uterine leiomyosarcoma, this is unheard of. These patients generally, as I mentioned, respond, if they do respond to chemotherapy, it's generally short-lived and the cancer progresses. And so a complete response nearly a decade later turns heads in this field. The other interesting thing was that these uterine leiomyosarcoma patients had somatic alterations rather than a germline alteration with a second hit, and the diseases that are best validated for being responsive to PARP inhibitors include the BRCA-associated diseases, the ones that you're at increased risk for if you have a germline BRCA mutation, including breast, pancreas, prostate, and ovarian. And so it was very interesting that this disease type that seemed to be uniquely sensitive to PARP inhibitors with immunotherapy was also different in that patients with uterine leiomyosarcoma don't tend to have a high frequency of BRCA alterations, and in patients that are born with a BRCA alteration, there doesn't seem to be a clearly increased risk of uterine sarcomas. So this population really jumped out as a uniquely sensitive population that differed from the prior indications for PARP inhibitors. Given this patient and these couple of patients that we observed on the combination, in addition to some other case reports and case series that had started to come out in small numbers, we wanted to look back at our large cohort of patients at Memorial Sloan Kettering to see if we could really get a better sense of the numbers. How many patients at Sloan Kettering with uterine sarcomas have BRCA alterations? Are they generally somatic or germline? Are there unique features about these patients in terms of their clinical characteristics? How many of them have received PARP inhibitors, and if so, is this just luck that these three patients did so well, or is this really a good treatment option for patients with BRCA-altered uterine sarcomas? And so we did this retrospective analysis identifying the patients at Sloan Kettering who met these criteria. So in total, we found 35 patients with uterine sarcomas harboring BRCA alterations, and the majority were leiomyosarcoma, about 86% of them had leiomyosarcoma, which is interesting because there are other uterine sarcomas, but it does seem like BRCA alterations tend to be more often in the leiomyosarcomas. And 13 of these patients with uterine leiomyosarcoma were treated with PARP inhibitors in the recurrent or metastatic setting with about half of those patients having an overall response, so that's a significant tumor shrinkage that sustained, and a clinical benefit rate of 62%. And if we look at the patients that had these BRCA2 deep deletions, which was the patient I had that had this amazing response, the overall response rate jumped to 60% and the clinical benefit rate to 80%. And we defined clinical benefit rate as having maintained on the PARP inhibitor without evidence of progression at six months. So this is really impressive for patients with a difficult to treat disease. And we couldn't do a randomized controlled trial comparing it to chemotherapy, but looking retrospectively at outcomes on chemotherapy studies, this was very favorable, particularly because many of these patients were heavily pretreated. So to get a sense of, you know, how this might compare to chemotherapy, we tried to use patients as their own internal controls, and we looked at how long patients were maintained on the PARP inhibitor as compared to how long they were on the treatment just prior. And we used a ratio of 1.3 to say if they were on the PARP inhibitor for 1.3 times what their previous treatment was or longer, that is pretty clearly better, more of a benefit from that regimen. And the majority of patients did meet that bar. So 58% had a PFS ratio greater than 1.3, and the average PFS ratio was 1.9, suggesting, you know, you would expect the the later lines of therapy to actually not work as well, but this suggests that it's actually working better than the immediately prior line of therapy, to me, suggesting that this is truly a good treatment option for these patients. Dr. Rafeh Naqash: Very interesting. And you mentioned that individuals with tumors having deep deletions were probably more responsive. How did you figure out that there was biallelic loss or deep deletions? Was that part of an extended analysis that was done subsequently? Dr. Alison Schram: So the deletions reported on our report, if it's a biallelic deletion, that is the one biallelic molecular alteration that would be reported. So those are, by definition, biallelic, and I think that that may be one of the reasons that's a good biomarker. But also, what's interesting is that if you have both copies deleted of BRCA, you can't develop reversion mutations. So one of the the known mechanisms of resistance to PARP inhibitors in patients who have BRCA alterations are something called a reversion mutation where, if you have a frameshift alteration, for example, in BRCA that makes BRCA protein nonfunctional, you can develop a second mutation that actually puts the DNA back in frame, and a functional protein is now made. And so a mechanism of resistance to PARP inhibitors is actually reverting BRCA to a wild-type protein, and then BRCA's synthetic lethality no longer makes sense and is no longer effective. But if you've deleted both copies of BRCA, you don't have the ability to restore the function, and you can't develop reversion mutations. And that's perhaps why, you know, my patient and others have had these prolonged responses to PARP inhibitors because you don't have the same ability to develop that mechanism of resistance. Dr. Rafeh Naqash: I remember thinking a year and a half back, I had an individual with prostate cancer and with BRCA2, and using liquid biopsy, I had a reversion mutation that we caught. In your practice, have you seen the utility of doing the serial liquid biopsies in these individuals to catch these reversion mutations? Dr. Alison Schram: Yes, absolutely. And in patients that have the ability to develop a reversion mutation, serial cell-free DNA can catch it, but the caveat is that it doesn't always. So if you see an acquired reversion mutation in cell-free DNA, that can be helpful, particularly if you're planning on putting the patient on another line of therapy that might require a dysfunctional BRCA. So if you're putting them on a clinical trial with a PARP combination and the rationale is that they're sensitive because they don't have a functional BRCA, you would want to know if they developed a reversion mutation, and serial cell-free DNA can definitely identify these reversion mutations. Some of the major clinical trials in ovarian cancer have done serial cell-free DNA and have demonstrated the utility of that approach. The caveat is that some of these reversion mutations are not readily caught on cell-free DNA because they're more complex reversion mutations, or they're not, the part of the gene that develops the reversion mutation is not tiled on the panel. And so it doesn't always catch the reversion mutations. Also, depends on the cell-free DNA shedding, depends on the tumor volume and other factors. And we published a related paper of a patient, it was a really interesting case of a patient with prostate cancer who was on a PARP inhibitor and developed what appeared to be a single reversion mutation on one sample, had negative cell-free DNA, single reversion mutation in a tissue biopsy, and then developed disease progression. And we did an autopsy, and the patient kindly consented to an autopsy, and at the time of autopsy, there were 10 unique reversion mutations identified across 11 metastases. So almost each metastasis had a unique reversion mutation, and only one of them had been seen premortem on a tissue biopsy and not on a cell-free DNA. But that autopsy really drove home to me how much we're missing by doing clinical testing in real time and we really don't know the entire genomic complexity of our patients by doing single samples. And theoretically, cell-free DNA can catch DNA from all the metastases, so you might think that that would be a solution, and it definitely can catch reversion mutations that are not seen in a single biopsy, but you really need to do it all. I mean, you need to do the tissue biopsy sampling, you need to do cell-free DNA, and probably one cell-free DNA test is not enough. Dr. Rafeh Naqash: Thank you, again, for that very nice explanation. Now, one quick provocative question. I remember when I was training, the lab that I used to work in, they used to do a lot of phosphorylation markers for DNA damage response, like phospho NBS, RAD51. Have you seen anything of that sort on these biallelic BRCA mutations where tumors are responding, but they also have a very high signature on the phosphorylation side, and it may or may not necessarily correspond to HRD signatures, but have you noticed or done any of that analysis? Dr. Alison Schram: I think that it would be great to do that analysis. And some of the work we're doing now is actually trying to dig a little bit deeper in our cohort of patients to understand are these HRD-positive tumors? Does HRD positivity correlate with response to BRCA alterations? In terms of the functional assays, I would love to be able to do a functional assay in these samples. One of the challenges is that this was a retrospective study and many of the patients were previously treated as standard of care or off-label with these agents, and so we didn't have prospective tissue collection, and so we're really limited by the tissue that was collected as part of standard of care and the consent forms that the patient signed that allow us to do genomic and molecular testing on their samples. So, I think that is hopefully future work that we will do and others will do. Dr. Rafeh Naqash: Sure. Shifting gears to your career trajectory, I'd like to spend a couple of minutes there before we end the podcast. So Dr. Schram, you've obviously been a trailblazer in this space of drug development, early-phase trials. Can you give us a brief synopsis of your journey and how you've successfully done what you're doing and what are some of the things that drive you? Dr. Alison Schram: Well, thank you for saying that. I don't know if that's true, but I'll take the bait. I've been interested in oncology since college and was always very interested in not only the science of oncology but of course, treating patients. And in medical school, I did basic science research in a laboratory and it was very inspiring and made me want to do research in oncology in addition to clinical care. When I became an oncology fellow, I was presented with a very difficult question, which is, “Do you want to be a lab PI and be in the lab, or do you want to do clinical care and clinical research?” And I couldn't choose. I found a mentor who thankfully really had this amazing vision of combining the two and doing very early drug development, taking the data that was being generated by labs and translating it into patients at the earliest stage. So, you know, phase one drug development in molecularly targeted therapies. And so I became very interested as a fellow in early drug development and this ability to translate brand new molecular insights into novel drugs. And I joined the- at Sloan Kettering, there was the Early Drug Development, it was actually a clinic, it was called something different, and it was very fortuitous. My last year of fellowship, the clinic became its own service with the ability to hire staff at Sloan Kettering, and I was the first ever hire to our Early Drug Development Service. And that really inspired me to try and bring these drugs to patients and to really translate the amazing molecular insights that my colleagues here at Sloan Kettering are discovering, and you know, of course, at other institutions and in pharma. And you know, there 's been an amazing revolution in in drug development over the last several years, and I feel very grateful that I've been here for it. You know, I've been able to take the brilliant insights from my colleagues and put these drugs in patients, and I have the amazing privilege of watching patients in many cases that benefit from these treatments. And so I do mostly phase one drug development and molecularly targeted therapies, and truthfully, I am just very fortunate to be around such brilliant people and to have both patients and labs trust me to be able to deliver these new drugs to patients and hopefully develop better drugs that move forward through FDA approval and reach patients across the country. Dr. Rafeh Naqash: Thank you so much. That was very nicely put. And hopefully our trainees and junior faculty find that useful based on their own career trajectories. Thank you, Dr. Schram, for joining us today. Hopefully, we'll see more of your subsequent work in JCO PO. Thank you for giving us all these insights today. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Alison Schram Disclosures Consulting or Advisory Role Company: Mersana, Merus NV, Relay Therapeutics, Schrodinger, PMV Pharma ,Blueprint Medicines, Flagship Pioneering, Redona Therapeutics, Repare Therapeutics, Endeavor BioMedicines Research Funding Company: Recipient: Your Institution  Merus, Kura, Surface Oncology, AstraZeneca, Lilly, Pfizer , Black Diamond Therapeutics, BeiGene, Relay Therapeutics, Revolution Medicines,  Repare Therapeutics, PMV Pharma, Elevation Oncology, Boehringer Ingelheim Travel, Accommodations, Expenses Company: PMV Pharma 

York's Ebor Meeting is back and so are the SBK Betting Podcast crew to give you all their best bets for the week ahead. With four Group 1 races to cover this is an action-packed episode. The Juddmonte International, Yorkshire Oaks, Nunthorpe Stakes, and City of York Stakes and Ebor Handicap all get their turn in the spotlight before handicap fancies and NAPs & NBs round off the podcast.Got a hot fancy for York yourself? Let us know... Hosted on Acast. See acast.com/privacy for more information.

China's industrial production maintained its solid growth momentum in July, with value-added output from major industrial enterprises rising 5.7 percent year-on-year and 0.38 percent month-on-month, driven by strong performances in equipment manufacturing and high-tech sectors, which expanded by 8.4 percent and 9.3 percent respectively, official data showed on Friday.周五公布的官方数据显示，中国7月份工业生产保持了强劲增长势头，主要工业企业增加值同比增长5.7%，环比增长0.38%，这得益于装备制造业和高科技行业的强劲表现，分别增长了8.4%和9.3%。 Figures released by the National Bureau of Statistics showed that China's industrial output, which includes manufacturing, mining and utilities, rose 5.7 percent year-on-year in July, following a 6.8 percent increase in June.国家统计局公布的数据显示，继6月份增长6.8%之后，中国7月份包括制造业、采矿业和公用事业在内的工业产出同比增长5.7%。 Retail sales, a key measure of consumer spending, grew 3.7 percent year-on-year in July compared to a 4.8 percent rise in June.零售额是衡量消费者支出的关键指标，7月份同比增长3.7%，而6月份增长4.8%。 Fixed-asset investment rose by 1.6 percent during the January-July period, compared to a 2.8 percent rise in the first half of the previous year.固定资产投资在1月至7月期间增长了1.6%，而去年上半年增长了2.8%。 The surveyed urban unemployment rate stood at 5.2 percent in July, up from 5 percent in June, according to the NBS.根据国家统计局的数据，7月份调查的城市失业率为5.2%，高于6月份的5%。 The NBS highlighted that the data reflects China's steady economic momentum, demonstrating significant resilience and vitality despite the complex and volatile external environment and the adverse impacts of extreme domestic weather conditions.国家统计局强调，这些数据反映了中国稳定的经济势头，尽管面临复杂多变的外部环境和极端国内天气条件的不利影响，但表现出了显著的韧性和活力。 Recognizing that challenges and risks persist in the external environment, the NBS reaffirmed its commitment to promoting the effective implementation of policies aimed at maintaining stability in employment, business activity, markets and expectations.国家统计局认识到外部环境持续存在挑战和风险，重申其致力于促进有效实施旨在维持就业、商业活动、市场和预期稳定的政策。 fixed-assetn.固定资产/ˈfɪkst ˈæsɛt/ external environmentn.外部环境/ɪkˈstɜːnəl ɪnˈvaɪrənmənt/

A State Council executive meeting presided over by Premier Li Qiang on Thursday called for stepping up efforts to improve the effectiveness of macroeconomic policies, while arranging the implementation of interest subsidies on personal consumption loans and loans to service sector businesses to better stimulate consumption and enhance market vitality.本周四，国务院常务会议主持李强总理呼吁加大力度提高宏观经济政策的有效性，同时安排对个人消费贷款和服务业企业贷款实施利息补贴，以更好地刺激消费，增强市场活力。As the country's latest step to boost innovation-driven growth, the State Council executive meeting approved a guideline on deeply implementing the AI Plus initiative, calling for promoting the large-scale, commercial application of artificial intelligence and advancing its accelerated adoption and deep integration across various fields of economic and social development.作为中国推动创新驱动增长的最新举措，国务院常务会议批准了一项关于深入实施人工智能+倡议的指导方针，呼吁促进人工智能的大规模商业应用，并推进其在经济和社会发展各个领域的加速采用和深度融合。On Thursday, the National Bureau of Statistics released the latest purchasing managers index, or PMI, data, which suggested the necessity to consolidate the resilience of the manufacturing sector and overall economic momentum in the second half of the year.周四，国家统计局发布了最新的采购经理人指数（PMI）数据，该数据表明，下半年有必要巩固制造业的韧性和整体经济势头。Economists called for further reinforcing support for domestic demand and employment, as the nation's manufacturing activity cooled in July amid unfavorable weather and the traditional off-season. The official PMI for the manufacturing sector stood at 49.3 in July, down from 49.7 in June, the NBS said on Thursday.经济学家呼吁进一步加强对国内需求和就业的支持，因为在不利天气和传统淡季的影响下，该国7月份的制造业活动有所降温。国家统计局周四表示，7月份制造业官方采购经理人指数为49.3，低于6月份的49.7。Despite the moderation, high-tech manufacturing continued to gain traction in July, highlighting the vitality of the country's industrial upgrading and reinforcing the sector's ability to withstand ongoing external challenges, experts said.专家表示，尽管有所放缓，但高科技制造业在7月份继续获得动力，突显了该国产业升级的活力，并增强了该行业抵御持续外部挑战的能力。Wang Qing, chief macroeconomic analyst at Golden Credit Rating International, said, "With both domestic and external demand softening, the manufacturing PMI ended its two-month rebound and declined within the contraction territory in July."东方金诚首席宏观经济分析师王青表示：“随着国内外需求疲软，制造业采购经理人指数结束了两个月的反弹，7月份在收缩区间内下降。”The official manufacturing PMI has stayed below the 50 mark that separates expansion from contraction for the fourth consecutive month. In July, the subindex of new orders — a barometer of market demand — dropped to 49.4 from 50.2 in June, while that of new export orders went down to 47.1 from 47.7 in the previous month.官方制造业采购经理人指数（PMI）连续第四个月保持在50分以下，50分是扩张与收缩的分界线。7月份，作为市场需求晴雨表的新订单分项指数从6月份的50.2降至49.4，而新出口订单分项指数从前一个月的47.7降至47.1。External headwinds dampened export momentum, while the effect of earlier policies to boost domestic demand started to wane in July, Wang said, adding that high temperatures, heavy rains and flooding in some regions disrupted production.王说，外部逆风抑制了出口势头，而早些时候提振内需的政策的效果在7月份开始减弱，并补充说，一些地区的高温、暴雨和洪水扰乱了生产。Downward pressures on economic growth may intensify in the third quarter, said Wang, who expects additional measures to boost domestic demand as China's relatively low levels of sovereign debt and inflation have offered ample policy room to offset a slowdown in external demand.王表示，第三季度经济增长的下行压力可能会加剧。他预计，随着中国相对较低的主权债务和通胀水平为抵消外部需求放缓提供了充足的政策空间，将采取额外措施提振内需。The Political Bureau of the Communist Party of China Central Committee held a meeting on Wednesday that made arrangements for economic work in the second half, emphasizing that macro policies should continue to exert force and be strengthened at an appropriate time.中共中央政治局周三召开会议，对下半年经济工作作出部署，强调宏观政策要继续发挥作用，适时加强。Xiong Yi, Deutsche Bank's chief economist for China, said, "If GDP growth slows faster than expected, a budget deficit increase may become necessary in the fourth quarter."德意志银行中国首席经济学家熊奕表示：“如果GDP增长放缓速度超过预期，第四季度可能需要增加预算赤字。”He said he anticipates that the Chinese economy will grow 4.8 percent in 2025, following its strong resilience in the first half of the year.他说，他预计中国经济在上半年强劲复苏后，到2025年将增长4.8%。According to Xiong, service consumption is expected to become a new driver of economic growth and employment in the second half of the year. China is enhancing its support for service consumption, with a particular focus on cultural tourism, elderly care, healthcare and domestic services.熊表示，服务消费有望成为下半年经济增长和就业的新动力。中国正在加强对服务消费的支持，特别关注文化旅游、养老、医疗保健和家政服务。Despite the overall decline, the PMI for high-tech manufacturing came in at 50.6 in July, while that for equipment manufacturing was at 50.3, the NBS said, indicating the sectors' capability to thrive despite challenges.国家统计局表示，尽管整体下降，但7月份高科技制造业的采购经理人指数为50.6，而设备制造业的PMI为50.3，表明这些行业在面临挑战的情况下仍有能力蓬勃发展。For instance, Nantong Haixing Electronics Co, an electronic energy storage materials producer based in Nantong, Jiangsu province, saw its export value exceeding 50 million yuan in the first half of 2025, marking a year-on-year increase of 67.23 percent, data from Nanjing Customs showed.例如，南京海关的数据显示，总部位于江苏省南通市的电子储能材料生产商南通海星电子有限公司在2025年上半年的出口额超过5000万元人民币（695万美元），同比增长67.23%。Jin Wenhui, the head of the company's foreign trade unit, said that despite intense worldwide competition, sustained investment in innovation has enabled the company to pursue industrial upgrading and remain resilient in a rapidly evolving global landscape.该公司外贸部门负责人金文辉表示，尽管全球竞争激烈，但对创新的持续投资使该公司能够追求产业升级，并在快速发展的全球格局中保持弹性。Guangdong Greenway Technology Co, a manufacturer of electric motorcycles and bicycles, as well as mobile energy storage systems, based in Dongguan, Guangdong province, shipped its products to more than 80 countries and regions across Europe and the Americas in the first half of the year, according to Huangpu Customs in Guangdong.广东黄埔海关表示，总部位于广东省东莞市的电动摩托车和自行车以及移动储能系统制造商广东绿道科技有限公司上半年将其产品运往欧美80多个国家和地区。Wu Jing, head of the company's foreign trade unit, said, "With years of development in lithium battery manufacturing, we've steadily increased our supply of high-quality, eco-friendly products amid the global shift toward energy transition, while actively exploring new markets and opportunities overseas."该公司外贸部门负责人吴京表示：“随着锂电池制造业多年的发展，在全球能源转型的背景下，我们稳步增加了高质量、环保产品的供应，同时积极探索海外新市场和机遇。”economic momentumn.经济势头/ˌiːkəˈnɒmɪk məˈmɛntəm/budget deficitn.预算赤字/ˈbʌdʒɪt ˈdɛfɪsɪt/

1-2부 [뉴스 신세계] 1. 尹, 4개월만에 내란특검에 재구속…법원 "증거인멸 염려" 2. 해병특검, 국방부·안보실 등 10여곳 압색...'尹 격노설' 조준 3. 이재명 대통령 국정 지지율 65%…윤석열 구속 찬성 71% [NBS] - 헬마우스 임경빈 작가 (출연) [이슈하이킥1] 윤석열 재구속·김건희 특검 수사…정국 전면전 돌입하나 - 신장식 조국혁신당 의원 (출연)

In the past six months, Nigeria recorded 222 mob-related killings, a 25% rise from last year, signaling a disturbing growth in jungle justice, according to the Nigeria Risk Index. Broader violent crime data from the NBS shows over 600,000 lives lost nationwide between May 2023 and April 2024. This episode of Nigeria Daily explores the root causes, legal stance, and possible solutions to Nigeria's deepening mob justice crisis.

For fem år siden lagde vi en av våre første landbrukstimer i SOSpodden. Gjest den gang var Tor Jacob Solberg, en av generalene i oppgjøret. Nå har han noen år bak seg som leder av NBS, og i denne episoden tar vi en liten recap av hva som har skjedd, og veien fremover. Tor Jacob doserer om slik han opplever landbruket, og det gir en god innsikt i hvordan en gruppe kjemper for sine interesser.Obs: Det ble noe tull med lyden helt i starten, men det kommer seg raskt! Hosted on Acast. See acast.com/privacy for more information.

China's price levels remained subdued in May, leaving ample room for further monetary easing and robust fiscal stimulus in the remainder of the year, analysts said on Monday.分析人士周一表示，中国5月份物价水平保持低位，为今年剩余时间进一步放松货币政策和实施强劲财政刺激措施留下了充足的空间。They said more policy support is needed to shore up demand in the world's second-largest economy, as policymakers navigate a more complicated and challenging external environment amid trade tensions with the United States.他们表示，在与美国贸易紧张局势加剧的背景下，决策者需要更多政策支持来提振全球第二大经济体的需求，因为政策制定者正在应对更加复杂和具有挑战性的外部环境。Their comments came as data released by the National Bureau of Statistics showed that the country's consumer price index, the main gauge of inflation, fell by 0.1 percent year-on-year in May, the same as in the previous month.他们发表上述言论之际，国家统计局发布的数据显示，5月份，作为通胀主要衡量指标的中国居民消费价格指数（CPI）同比下降0.1%，与上月持平。Wen Bin, chief economist at China Minsheng Bank, linked the subdued consumer prices to seasonal factors and a decline in oil prices, while noting the improvement in core CPI, suggesting the resilience of the domestic economy.中国民生银行首席经济学家温彬将CPI低迷归因于季节性因素和油价下跌，同时指出核心CPI的改善表明国内经济具有韧性。The core CPI, which excludes volatile food and energy prices and is deemed a better gauge of the demand-supply relationship, increased 0.6 percent year-on-year in May, up from a 0.5 percent rise in April, NBS data showed.国家统计局数据显示，剔除食品和能源价格的核心CPI同比上涨0.6%，较4月份的0.5%进一步回升，被视为衡量供需关系的更优指标。On factory-gate prices, Wen said the decline reflected ongoing imported price pressures. "Although risk appetite increased early in the month due to favorable progress in US-China talks, with a slight rebound in commodity prices, excluding gold, commodity prices later dropped again as tariff threats resurfaced," he said.关于出厂价格，温彬表示，CPI的下降反映了持续的进口价格压力。他表示：“尽管本月初受中美贸易谈判取得积极进展的影响，风险偏好有所回升，除黄金以外的大宗商品价格略有反弹，但随着关税威胁再次浮现，大宗商品价格随后再次下跌。”China's producer price index, which gauges factory-gate prices, dropped by 3.3 percent year-on-year in May, widening from a 2.7 percent fall in April, the NBS said.国家统计局表示，衡量出厂价格的中国5月份生产者价格指数（PPI）同比下降3.3%，降幅较4月份2.7%的降幅有所扩大。Looking ahead, Wen said he expects CPI to rebound modestly but remain low in the near term, saying supportive macroeconomic policies would bolster core CPI growth.展望未来，温彬表示，他预计CPI将小幅反弹，但短期内仍将维持低位，并表示支持性的宏观经济政策将支撑核心CPI的增长。"A combination of incremental and existing policy measures are working in tandem to improve the supply-demand structure, which will support prices in relevant sectors. Increased travel demand during the summer will also drive up service prices."“增量与存量政策工具协同发力，将改善供需结构，对相关行业价格形成支撑。暑期出行需求上升也将带动服务类价格上涨。”As for PPI, Wen said conditions may gradually improve, though a return to positive territory will take time.关于PPI，温彬认为，尽管整体环境或将逐步改善，但短期内难以迅速转正。Considering base effects and current trends in consumer goods, energy, and industrial prices, Feng Lin, executive director of the research and development department at Golden Credit Rating International, said she expects consumer prices to remain flat in June, with the year-on-year drop in PPI likely staying around 3.3 percent.东方金诚国际信用评估有限公司研究发展部执行总监冯琳预计，考虑到基数效应以及当前消费品、能源和工业品价格走势，预计6月份CPI环比持平，PPI同比降幅仍将维持在3.3%左右。"With overall prices staying at low levels, promoting a reasonable rebound in prices will become an important macro policy goal in the second half of the year," she said. "This also opens up room for more proactive fiscal policies to boost consumption and investment, as well as further interest rate cuts by the central bank."她表示：“在物价总体处于低位运行的背景下，推动物价合理回升将成为下半年宏观政策的重要目标。这也为央行进一步采取更积极的财政政策刺激消费和投资，以及进一步降息提供了空间。”Yuan Haixia, dean of the research institute at rating agency CCXI, said that China continues to face a complex and challenging external environment while domestic cyclical and structural economic issues remain intertwined.中诚信国际研究院院长袁海霞表示，中国外部环境依然复杂严峻，国内经济周期性问题和结构性问题依然交织。While production remains relatively strong, domestic demand is only marginally improving and still weak overall as shown by subdued price levels, despite resilient external demand, Yuan said. "Policymakers should take advantage of the current policy window and intensify countercyclical measures in the short term."袁海霞表示，尽管生产保持相对强劲，但国内需求仅略有改善，整体来看仍然疲软，价格水平低迷是其主要表现，而外部需求保持韧性。“政策制定者应抓住当前政策窗口，短期内加大逆周期调节力度。”Yuan said that there is still scope for one to two more cuts in the reserve requirement ratio and interest rates during the remainder of the year, given the country's relatively high real interest rates amid low inflation and its ample policy space compared to economies like the United States and Japan.袁海霞表示，考虑到当前实际利率偏高、通胀较低，同时与美日等国相比，我国政策空间仍较为充裕，年内仍有1至2次降准降息的空间。On the fiscal front, stronger central government fiscal support is needed to expand domestic demand while around 1 trillion yuan ($139.22 billion) in additional fiscal funding could be introduced at a proper time to stabilize growth and improve expectations, she said.她表示，在财政方面，中央政府需要加大财政支持力度，扩大内需，同时可以适时新增约1万亿元人民币（约合1392.2亿美元）的财政资金，以稳定增长并改善预期。Yuan added that a balanced approach to encourage both consumption and investment is needed. Measures could include short-term cash subsidies, midterm tax reforms, and long-term improvements in income distribution to boost consumption. In parallel, investment priority should shift from physical infrastructure toward human capital, with a focus on raising investment efficiency.袁海霞补充说，需要采取均衡的政策措施，鼓励消费和投资。措施可能包括短期现金补贴、中期税制改革以及长期改善收入分配以刺激消费。同时，投资重点应从物质基础设施转向人力资本，并注重提高投资效率。stimulus/ˈstɪmjələs/n.刺激（措施）；促进因素resilience/rɪˈzɪliəns/n.韧性；恢复力countercyclical/ˌkaʊntərˈsɪklɪkəl/adj.逆周期的gauge/ɡeɪdʒ/n.指标；标准；衡量工具

Haciendy z eurofondov sa podozrivo koncentrujú okolo Nitry, upozorňuje expremiér a europoslanec za PS Ľudovít Ódor. Podľa neho Európa vidí, že sme doterajšie eurofondy rozkradli a utopili. Nehrozí však zastavenie eurofondov, ale čosi úplne iné a ešte horšie: Že nám európski daňoví poplatníci odmietnu posielať eurofondy na ďalších 7 rokov, prípadne nám výrazne znížia ich objem. Slovensko čakajú ďalšie konsolidácie. Ako by v budúcej vláde konsolidovalo PS a ktoré dane by zvýšilo?V podcaste sa dozviete:– od 1. minúty – že Andrej Danko má podľa neho výtlak ako malé pivo;– po 3:00 – ako nám dvojtvárna politika Roberta Fica spôsobuje hanbu;– po 4:00 – že keď ľudia musia viac pracovať, to nie je konsolidácia;– od 5:00 – ako jednoduchému človeku vysvetliť, prečo je transakčná daň hlúposť;– po 10:00 – že akékoľvek kontroly vníma pozitívne, aj tie z europarlamentu;– od 10:30 – že haciendy z eurofondov sa podozrivo koncentrujú okolo Nitry;– po 13:20 – či Slovensku naozaj hrozí stopnutie eurofondov;– od 14:00 – že dôležitejší bude európsky 7-ročný rozpočet, v ktorom nám už Nemci nebudú chcieť posielať peniaze na rozkrádanie;– po 16:30 – že Peter Kažimír nemá pokračovať vo funkcii guvernéra NBS;– od 17:00 – či predtým kolegu a šéfa Kažimíra považoval za bezúhonného odborníka, ktorého sa nedotkli kauzy Smeru;– po 19:00 – prečo ho nezaujímali Kažimírove domy v hodnote troch miliónov;– od 21:30 – že Slovensko čaká ďalšia a ďalšia konsolidácia;– po 23:30 – ako bude v budúcnosti konsolidovať Progresívne Slovensko;– od 25:00 – že konsolidovať sa musí aj v zdravotníctve;– po 28:00 – ktoré konkrétne dane by zvyšovalo PS;– po 31:00 – či je Peter Pellegrini prezidentom vojny;– od 32:00 – že na obranu by sa malo investovať duálne, ale do technológií;– po 34:00 – že kto chce mier, sa musí pripravovať na vojnu;– od 36:00 – či sa máme na hranicu s Maďarskom pozerať ako na rizikovú;– po 38:50 – že Ficove zmeny ústavy sú hry z hesla chlieb a hry;– od 41:00 – že oproti europarlamentu na Slovensku riešime blbosti;– po 43:00 – aká je ekonomická vízia PS do najbližšej budúcnosti;– od 46:00 – že nesmieme nechať odísť každého tretieho stredoškoláka.

Haciendy z eurofondov sa podozrivo koncentrujú okolo Nitry, upozorňuje expremiér a europoslanec za PS Ľudovít Ódor. Podľa neho Európa vidí, že sme doterajšie eurofondy rozkradli a utopili. Nehrozí však zastavenie eurofondov, ale čosi úplne iné a ešte horšie: Že nám európski daňoví poplatníci odmietnu posielať eurofondy na ďalších 7 rokov, prípadne nám výrazne znížia ich objem. Slovensko čakajú ďalšie konsolidácie. Ako by v budúcej vláde konsolidovalo PS a ktoré dane by zvýšilo?V podcaste sa dozviete:– od 1. minúty – že Andrej Danko má podľa neho výtlak ako malé pivo;– po 3:00 – ako nám dvojtvárna politika Roberta Fica spôsobuje hanbu;– po 4:00 – že keď ľudia musia viac pracovať, to nie je konsolidácia;– od 5:00 – ako jednoduchému človeku vysvetliť, prečo je transakčná daň hlúposť;– po 10:00 – že akékoľvek kontroly vníma pozitívne, aj tie z europarlamentu;– od 10:30 – že haciendy z eurofondov sa podozrivo koncentrujú okolo Nitry;– po 13:20 – či Slovensku naozaj hrozí stopnutie eurofondov;– od 14:00 – že dôležitejší bude európsky 7-ročný rozpočet, v ktorom nám už Nemci nebudú chcieť posielať peniaze na rozkrádanie;– po 16:30 – že Peter Kažimír nemá pokračovať vo funkcii guvernéra NBS;– od 17:00 – či predtým kolegu a šéfa Kažimíra považoval za bezúhonného odborníka, ktorého sa nedotkli kauzy Smeru;– po 19:00 – prečo ho nezaujímali Kažimírove domy v hodnote troch miliónov;– od 21:30 – že Slovensko čaká ďalšia a ďalšia konsolidácia;– po 23:30 – ako bude v budúcnosti konsolidovať Progresívne Slovensko;– od 25:00 – že konsolidovať sa musí aj v zdravotníctve;– po 28:00 – ktoré konkrétne dane by zvyšovalo PS;– po 31:00 – či je Peter Pellegrini prezidentom vojny;– od 32:00 – že na obranu by sa malo investovať duálne, ale do technológií;– po 34:00 – že kto chce mier, sa musí pripravovať na vojnu;– od 36:00 – či sa máme na hranicu s Maďarskom pozerať ako na rizikovú;– po 38:50 – že Ficove zmeny ústavy sú hry z hesla chlieb a hry;– od 41:00 – že oproti europarlamentu na Slovensku riešime blbosti;– po 43:00 – aká je ekonomická vízia PS do najbližšej budúcnosti;– od 46:00 – že nesmieme nechať odísť každého tretieho stredoškoláka.

Prezident Peter Pellegrini predniesol svoju prvú správu o stave republiky - vládu pochválil za stavbu nemocníc či opravu ciest a skritizoval za zahraničnú politiku. Povedal, že pri politike na štyri svetové strany sa musíme pozerať najmä na západ.Súd odsúdil guvernéra NBS a bývalého ministra financií za Smer Petra Kažimíra za korupciu.A skupina zahraničných europoslancov prišla na Slovensko debatovať aj o využívaní, respektíve zneužívaní, eurofondov - od Matúša Šutaja Eštoka si vypočuli, že sú trestnou výpravou a Andrej Danko zašiel ešte ďalej, keď jedného z nich nazval českým slovom “vůl”.Rovnako nevkusne sa vyjadrovali slovenskí politici aj o nemeckom kancelárovi Friedrichovi Merzovi, ktorý hrozí Slovensku zablokovaním eurofondov.Premiér Fico odkazuje, že nie je malý žiačik, ktorého treba poučovať. Pobočka Smeru nazvala Merza "führerom". A máme tu aj ďalšie vyjadrenie o vystúpení z EÚ - tentokrát s tým prišiel šéf SNS Danko.Sobotným Dobrým ránom vás sprevádzajú Zuzana Kovačič Hanzelová a Jakub Filo.Otázky do nasledujúcej epizódy Dobrého rána sobota nám zasielajte na e-mail dobrerano@sme.sk, ideálne vo forme hlasovej správy. Do predmetu napíšte Otázka do sobotného Dobrého rána.Zdroje zvukov: TA3, Denník N, Facebook/Robert Fica, Matúš Šutaj Eštok, Telegram/Lukáš Machala–Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠–Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifing⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

[뉴스 신세계] 1) 국힘 단일화 갈등에 김문수 측, ‘대선후보 지위 인정' 가처분 신청 1-1) 권영세 “단일화 안되면 이번 대선 기호 2번 없어져” 1-2) 김문수-한덕수, 오후 4시반 국회서 2차 담판 2) 김상욱, 국민의힘 탈당… “이재명·이준석 만나고 싶다” 3) ‘삼자대결'서 이재명 44% 한덕수 34%… 이재명 43% 김문수 29% [NBS] - 헬마우스 임경빈 작가 [거침없이 하이킥] 계속되는 국힘 ‘단일화' 갈등… 어떻게 정리될까? - 장윤선 정치전문기자, 장성철 공론센터 소장

V tejto časti podcastu som sa rozprával s Jurajom Hrbatým, zakladateľom a CEO spoločnosti Finax, ktorá priniesla revolúciu do sveta investovania na Slovensku. Juraj nám priblížil, ako sa z nespokojnosti s tradičnými finančnými službami zrodila myšlienka vytvoriť Finax – prvého slovenského robo-poradcu, ktorý sprístupnil pasívne investovanie širokej verejnosti. Juraj začal podnikať po tom, čo prekonal rakovinu. Tá mu podľa jeho slov otvorila oči. Diskutovali sme o jeho podnikateľskej ceste, ktorá sa začala po rokoch v zamestnaní. Pokecali sme o výzvach pri budovaní firmy a o tom, ako sa mu podarilo získať dôveru investorov. V podcaste spomína Juraj historku, ktorá hovorí o tom, že samotná NBS nechápala a neverila konceptu investovania online.V rozhovore sme sa venovali aj tomu, ako Finax expandoval na zahraničné trhy a aké stratégie využíva na udržanie rastu. Juraj zdôraznil význam emócií v investovaní a vysvetlil, prečo je dôležité mať jasne stanovené investičné ciele. Dobré investovanie by podľa Juraja mala byť nuda aj napriek tomu, že množstvo ľudí hľadá skratky a špekuluje so stratégiami. Hovorili sme aj o investovaní do nehnuteľností. To podľa Juraja nemá zmysel z dôvodu, že pri ETF z dlhodobého horizontu môžu ľudia získať rovnaký podiel bez starostí. Podelil sa aj o víziu Finaxu, ktorá chce, aby ľudia investovali viac, jednoduchšie a s jasným cieľom.V závere sme sa dotkli tiež témy investovania do slovenských firiem. Juraj zdôraznil dôležitosť tejto témy a spôsobu, ako na to. Táto epizóda je plná praktických rád a inšpirácie pre každého, kto sa zaujíma o investovanie a príbeh Finaxu.---------------------------------------------------------------------------Kapitoly:00:00:00 – Predstavenie hosťa00:01:31 – Investovanie do vlastných firiem00:05:43 – Ako vznikol Finax?00:14:19 – Otravní finanční poradcovia00:19:25 – Biznis v zahraničí zo Slovenska00:26:23 – Ako živiť rast kapitálom?00:31:41 – Vízia Finaxu00:39:24 – Investovanie na vlastnú päsť00:49:10 – Emócie v investovaní00:52:06 – Rozloženie a výber investícií01:02:24 – Investovanie do slovenských firiem01:11:07 – Čo odporúča Juraj Hrbatý?01:15:18 – Zmysel života podľa Juraja Hrbatého---------------------------------------------------------------------------Viac z podcastov nájdete na:https://www.truban.sk/podcast/---------------------------------------------------------------------------Všetky spomenuté knihy a podcasty nájdete v článku na blogu:https://wp.me/p5NJVg-QH---------------------------------------------------------------------------Podcast si môžete vypočuť aj na streamovacích platformách:● Spotify ▸ https://spoti.fi/31Nywax ● Apple podcast ▸ https://apple.co/3n0SO8F---------------------------------------------------------------------------● Najlepšie z podcastu na Instagrame ●https://www.instagram.com/truban.podcast/● Truban.sk ●https://bit.ly/3r1vYQJ ● Instagram ●https://www.instagram.com/truban/● Facebook ●https://www.facebook.com/miso.truban● LinkedIn ●https://sk.linkedin.com/in/truban

Business-as-usual this morning as TDS sufferers freak about the President, his interview w/ NBS's Kristen Welker being the chief trigger. And then there's that little thing about the Pope.

YiFan Li comes on to talk about the strength we've seen in GDT/SGX prices and NBS data suggesting milk production in China was up 1.7% during the first quarter.

[뉴스 신세계] 1) 법원, 尹 공판 촬영 허가… 변호인단, “무죄추정 원칙 위배” 반발 2) 헌재, 헌법재판관 지명 가처분 전원일치 인용… 철회 입장 없는 한덕수? 2-1) 국민의힘, 경선 토론 대진표 확정 3) 정권교체 54% 재창출 33%… 이재명 39%, 홍준표·김문수 8%[NBS] - 헬마우스 임경빈 작가 [거침없이 하이킥] 헌재 가처분 인용… 한덕수 대행은 왜 그랬을까? - 장윤선 정치전문기자, 장성철 공론센터 소장

There are two state conventions going on the through the weekend of April 5 where young adults are preparing and competing for their futures. Click on the podcast to learn more about what drives Montana’s young adults, as NBS’s Joe […] The post Young Adults Prepping, Competing for Their Futures first appeared on Voices of Montana.

This week on The Sneaker Podcast, the squad thinks of breaking out all their NBs, we find out what hunter-killer might be about, and we go back and remember the last time particular sneaker situations happened to us! Time to turn back time! Time to turn it up!   The sponsors: Our favorite streetwear https://kuwallatee.com/ Our favorite hat shop https://www.styll.ca/   Instagram: https://www.instagram.com/thesneakerpodcast/   The Crew: https://www.instagram.com/misterqmart/ https://www.instagram.com/justkalby/ https://www.instagram.com/po.tato/ https://www.instagram.com/christopher.chiu/   YouTube: https://www.youtube.com/c/TheSneakerPodcast   Twitter: https://twitter.com/thesneakerpod   Facebook: https://www.facebook.com/thesneakerpodcast/   #TheSneakerPodcast

Trump pozastavil vojenskú pomoc Ukrajine, prerušil aj zdieľanie spravodajských informácií s Ukrajinou. Vyzerá to tak, že momentálne je americký prezident viac v línii s Ruskom, než so Západom či Ukrajinou.V tomto znamení bol aj summit tento týždeň, lídri EÚ sa zhodli na vyhlásení, ktoré sľubuje ďalšiu podporu Ukrajine. Všetci lídri v dohodnutom texte o obrane súhlasili s výrazným zvýšením príspevkov na prezbrojenie Európy, premiér Fico najprv hrozil vetovaním, ale nakoniec vyhlásenie podporil výmenou za to, že v texte sa spomína preprava plynu z Ruska cez Ukrajinu.Jediný, kto text vetoval, bol maďarský premiér Viktor Orbán. A veci sa dejú aj doma, europoslanec Smeru Erik Kaliňák pobúril výrokmi o tom, že Rusi na našich hraniciach, teda na Ukrajine, by znamenali, že Slovensko by malo konečne spoľahlivého suseda, Ľuboš Blaha je opäť na návšteve v Moskve, a vláda má nového ministra - Rudolf Huliak sa stal ministrom športu. Odvolaný Dušan Keketi by sa mal stať viceguvernérom NBS.Sobotným Dobrým ránom vás sprevádzajú Zuzana Kovačič Hanzelová a dnes s hosťujúcim spolumoderátorom Samom Marecom.Otázky do nasledujúcej epizódy Dobrého rána sobota nám zasielajte na e-mail dobrerano@sme.sk, ideálne vo forme hlasovej správy. Do predmetu napíšte Otázka do sobotného Dobrého rána.Zdroje zvukov: 360tka, RTVS, TV Markíza, TASR–Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠–Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifing⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

[뉴스 연구소] 尹 체포적부심 기각/ 내란특검 합의될까?/ 이스라엘-하마스 전쟁 종식- 경향신문 박순봉 기자, 김준일 시사 평론가 [인터뷰 (1)] 조사 거부하는 尹/ 조기 대선 국면 전환?/ 민주 ‘내란특검’ 국힘 ‘비상계엄특검’- 국민의힘 안철수 의원 [놓지마 뉴스]- 방송인 강승희 [뉴스 게임] 尹의 악수? 수사 비협조·체포적부심 신청/ NBS 국힘 35% vs 민주 33%?- 최재성 前 정무수석- 국민의힘 김성태 前 원내대표 [탐정 손수호] 尹의 법기술: 체포적부심·서부지방법원·조사 거부·구속영장- 법무법인 ‘지혁’ 손수호 변호사 (법학 박사) [미니 댓꿀쇼] 탄핵 심판 결과 예상/ 포고령 1호 엇갈린 주장- 법무법인 ‘지혁’ 손수호 변호사 (법학 박사)See omnystudio.com/listener for privacy information.

Yippie-ki-yay, old time radio fans! We're heading west for some radio mysteries set in the wide open spaces of the American frontier. Alan Ladd is on the trail of his brother's murderer in "A Killing in Abilene" from Suspense (originally aired on CBS on December 14, 1950), and Joel McCrea hunts for a cowboy's killer in "The Cactus Pear" from Tales of the Texas Rangers (originally aired on NBC on December 17, 1950). As Yours Truly, Johnny Dollar, Edmond O'Brien has to determine if - and why - a rancher's wife bumped off her husband in "The Jarvis Wilder Matter" (originally aired on CBS on February 24, 1951), and William Conrad has to clear his own name in "Matt for Murder" from Gunsmoke (originally aired on CBS on July 26, 1954). Finally, Jack Webb stars in an urban western as the police face off against an armed and delusional man who believes he's defending a fort against the Indians in "The Big Cowboy" from Dragnet (originally aired on NBS on June 1, 1954). Click here for some of my original audio comedy, including some old time radio show parodies!